🌟 Yesterday, our CEO, Dr. Daniel Vitt, gave the keynote speech at the Life Science Pitch Day 2024 at the IZB - Innovation and Start-up Center Biotechnology in Munich! 🧬 Daniel shared insights on Immunic’s journey from concept stages and foundation to being a late-stage clinical phase 3 company listed on Nasdaq. 🚀 💡 Curious? Learn more about IMUX here ➡️ www.imux.com #LifeSciences #DrugDevelopment #Nasdaq HTGF | High-Tech Gründerfonds #IZB #LSPitchDay2024 #Munich #IMUX #Immunic
Immunic Therapeutics
Biotechnology Research
New York City, New York 6,107 followers
Immunic is a biotechnology company developing small molecule therapies for chronic inflammatory and autoimmune diseases
About us
Immunic (Nasdaq: IMUX) is a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases. Privacy Policy: https://imux.com/privacy-policy/
- Website
-
https://imux.com
External link for Immunic Therapeutics
- Industry
- Biotechnology Research
- Company size
- 51-200 employees
- Headquarters
- New York City, New York
- Type
- Public Company
- Founded
- 2016
Locations
-
Primary
1200 Avenue of the Americas
Suite 200
New York City, New York 10036, US
-
Lochhamer Schlag 21
Gräfelfing, Bayern 82166, DE
Employees at Immunic Therapeutics
Updates
-
✨ We are excited to see the recent appointment of Jason Tardio as our new Chief Operating Officer and President displayed on the Nasdaq tower in New York City. 🏙️ Thank you, Nasdaq, for your continuous support! Congratulations, again, to Jason and welcome to the IMUX team! #IMUX #Immunic #ChiefOperatingOfficer #Nasdaq #NasdaqListed #NewYork #Grateful 🙏
-
-
🌾 News for celiac disease patients! In a phase 1b clinical trial, Immunic's drug candidate, IMU-856, showed positive effects in four main dimensions of clinical outcome in celiac disease: 🛡️ Protected gut architecture 🌟 Improved symptoms 📊 Boosted biomarker response 🍽️ Enhanced nutrient absorption Do you want to learn more? Our comprehensive presentation during Digestive Disease Week® (DDW) will give you all the insights! 🌾 💚 ➡️ https://bit.ly/3XGngaX #Gastroenterology #gut #Celiac #CeliacDisease #symptoms #biomarker #nutrient #IMU856 #Immunic #IMUX #DigestiveDiseaseWeek #DDW #DDW2024
-
-
🌾 News for celiac disease patients! In a phase 1b clinical trial, Immunic's drug candidate, IMU-856, showed positive effects in four main dimensions of clinical outcome in celiac disease: 🛡️ Protected gut architecture 🌟 Improved symptoms 📊 Boosted biomarker response 🍽️ Enhanced nutrient absorption Do you want to learn more? Our comprehensive presentation during Digestive Disease Week® (DDW) will give you all the insights! 🌾 💚 ➡️ https://bit.ly/3XGngaX #Gastroenterology #gut #Celiac #CeliacDisease #symptoms #biomarker #nutrient #IMU856 #Immunic #IMUX #DigestiveDiseaseWeek #DDW #DDW2024
-
-
Thank you, Leerink Partners, for hosting us at the "Therapeutics Forum: I&I and Metabolism"! We had very productive 1x1 meetings 🤝, and enjoyed the experts' valuable insights shared during the KOL panels. 💡 We already look forward to next year's event! Dr. Daniel Vitt, Jessica Breu, Glenn Whaley #Immunology #Inflammation #HealthcareInnovation #Immunic #IMUX #InvestorRelations #Partnering
-
📖 We invite you to explore Sheryl Sheth's latest article published on TipRanks, discussing the progress and potential future direction of Immunic’s clinical trials in multiple sclerosis. This comprehensive article covers the current status of our lead asset and outlines upcoming milestones. Read the full article here: https://bit.ly/45VET8K #MultipleSclerosis #MS #PMS #RMS #Vidofludims #IMU838 #Immunic #IMUX #Innovation #TipRanks
-
-
🚀 Exciting News from Immunic! 🚀 We are thrilled to welcome Jason Tardio as our new Chief Operating Officer and President. With a wealth of experience, most notably related to the launch and commercialization of successful multiple sclerosis drugs, and a history of significant out-licensing transactions, Jason is poised to drive our mission forward. He will lead internal efforts to prepare for the potential launch of vidofludimus calcium and also work closely with Patrick Walsh, Chief Business Officer, to prepare the company for a range of potential partnership outcomes. Additionally, we are proud to announce the promotion of Werner Gladdines to Chief Development Officer. Werner's dedication and expertise in clinical operations have been instrumental for our progress, and we look forward to his continued leadership in this expanded role. ➡️ https://bit.ly/3WdIV90 #Teamwork #HR #Leadership #Biotech #Immunic #IMUX #vidofludimus #IMU838 #IMU856 #IMU381 #commercialization #partnership #MultipleSclerosis #MS
-
-
📢 Meet the Immunic team at the Leerink Partners "Therapeutics Forum: I&I and Metabolism" on 📅 Tuesday, July 9th & Wednesday, July 10th at 📍The Boston Harbor Hotel, Boston, MA. 🌊 Dr. Daniel Vitt, CEO & President, and Jessica Breu, VP Investor Relations & Communications, will be participating in the conference. This forum will feature 1x1 meetings and KOL panels diving into the latest therapeutic themes and debates in Immunology & Inflammation (I&I) and Metabolic diseases. 👋 #Immunology #Inflammation #HealthcareInnovation #Immunic #IMUX #InvestorRelations #Boston
-
-
🇺🇸 Happy 4th of July from all of us at Immunic! 🎆 🎉 Wishing everyone a safe and joyous Independence Day filled with celebration, gratitude, and togetherness. 🎇 #4thOfJuly #FourthOfJuly #July4th #IndependenceDay #IMUX #Immunic
-
-
💡 Discover TipRanks reporter Sheryl Sheth's deep dive into Immunic's lead program aimed at treating relapsing and progressive forms of multiple sclerosis. Vidofludimus calcium has already shown signs of neuroprotective, anti-inflammatory, and anti-viral effects in clinical testing and is currently being investigated in phase 3 and phase 2 trials. Do you want to learn more? Read the full article here: ➡️ https://bit.ly/3xyv8k6 #MultipleSclerosis #MS #RMS #PMS #Neurology #Immunic #IMUX #Vidofludimus
-